Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

This article was originally published in The Pink Sheet Daily

Executive Summary

Embracing patient community recommendations, FDA draft guidance says historically controlled trials may support efficacy in some cases.

Advertisement

Related Content

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'
Patient-Driven Drug Development Requires New Transparency Policies
Duchenne Development: Six-Minute Walk Losing Favor?

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS078564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel